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Abstract: Background: Malignant pleural mesothelioma (MPM) is driven by the inactivation of tumor
suppressor genes (TSGs). An unmet need in the field is the translation of the genomic landscape into
effective TSG-specific therapies. Methods: We correlated genomes against transcriptomes of patients’
MPM tumors, by weighted gene co-expression network analysis (WGCNA). The identified aberrant
biochemical networks and potential drug targets induced by tumor suppressor loss were validated
by integrative data analysis and functional interrogation. Results: CDKN2A/2B loss activates G2/M
checkpoint and PI3K/AKT, prioritizing a co-targeting strategy for CDKN2A/2B-null MPM. CDKN2A
deficiency significantly co-occurs with deletions of anti-viral type I interferon (IFN-I) genes and
BAP1 mutations, that enriches the IFN-I signature, stratifying a unique subset, with deficient IFN-I,
but proficient BAP1 for oncolytic viral immunotherapies. Aberrant p53 attenuates differentiation and
SETD2 loss acquires the dependency on EGFRs, highlighting the potential of differentiation therapy
and pan-EGFR inhibitors for these subpopulations, respectively. LATS2 deficiency is linked with
dysregulated immunoregulation, suggesting a rationale for immune checkpoint blockade. Finally,
multiple lines of evidence support Dasatinib as a promising therapeutic for LATS2-mutant MPM.
Conclusions: Systematic identification of abnormal cellular processes and potential drug vulnerabilities
specified by TSG alterations provide a framework for precision oncology in MPM.
Keywords: mesothelioma; tumor suppressor; targeted therapy; immunotherapy
1. Introduction
Malignant pleural mesothelioma (MPM) is a deadly cancer with incidence and mortality still
increasing globally [1]. The leading cause for the poor prognosis of MPM is the extreme dearth of
effective treatment options. The great majority of MPM patients present with advanced diseases,
for whom a chemotherapy regimen (cisplatin plus pemetrexed) established in 2003 remains the only
clinically approved first-line therapy [2].
Comprehensive genomic studies in MPM have revealed a rarity of pharmacologically tractable
mutations in oncogenes [3–5], but the prevalence of inactivating alterations in tumor suppressor
genes (TSGs), e.g., cyclin-dependent kinase inhibitor 2A/2B (CDKN2A/2B), BRCA1-associated protein-1
(BAP1), neurofibromin 2 (NF2), tumor protein p53 (TP53), SET domain containing 2 histone lysine
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methyltransferase (SETD2) and large tumor suppressor kinase 2 (LATS2). While the pharmacological
inhibition of oncoproteins is successful, targeted therapies that exploit abnormal TSGs have proven far
more difficult. Precision oncology, a burgeoning effort aimed at targeting unique molecular alterations
of individual patients, has achieved great success in many cancers, but significantly lags behind in
MPM. Consequently, clinical trials in MPM without biomarker-directed stratifications have generally
failed [6–9].
Although the direct intervention of tumor suppressors is challenging, aberrant TSGs induce the
reprogramming of biochemical networks, which creates cancer-specific vulnerabilities and provides an
alternative venue for precision oncology in TSG-driven cancer [10]. Systematic correlation analysis is
a powerful tool to identify rewired cellular processes, potential therapeutic targets, and associated
biomarkers [11]. Here, by implementing weighted gene co-expression network analysis (WGCNA) [12],
paralleled by comprehensive data mining and functional interrogation, we systematically delineated
the biochemical networks induced by the inactivation of major TSGs (CDKN2A/2B, BAP1, NF2, TP53,
SETD2, and LATS2) in MPM, and the underlying implications for precision oncology. Identification of
molecular traits and the associated drug vulnerabilities co-selected by the functional loss of specific
TSGs provides unprecedented insights into MPM pathobiology and may promote personalized
treatment of MPM patients with molecularly guided, targeted- and immuno-therapy.
2. Results
2.1. Systematic Analysis of Rewired Biochemical Networks and Therapeutic Vulnerabilities Enabled by Tumor
Suppressor Loss in MPM
All the major genetic alterations (>10%) occurring in TCGA MPM cohort are TSGs, including
CDKN2A/2B (homozygous deletions (HDs)), BAP1 (HDs and point mutations), NF2 (HDs and point
mutations), TP53 (point mutations), SETD2 (HDs and point mutations), and LATS2 (HDs and point
mutations) (Figure 1A). Notably, there are substantial overlaps of alterations in different TSGs
(Figure 1B). For instance, the majority (67.6%) of the MPM tumors that harbor HDs of CDKN2A/2B
have co-occurring alterations in other TSGs, e.g., BAP1 (40.5%) or NF2 (37.8%). Importantly, analyses
of RPPA data of TCGA MPM cohort (n = 61) showed that genetic alterations remarkably decreased the
levels of the encoded proteins or downstream effectors (Figure 1C).
To uncover fundamental molecular features associated with the functional loss of TSGs in MPM,
we performed WGCNA, based on the transcriptomic data of TCGA MPM cohort (Figure 1D and
Figure S1A–D), and delineated a network of multiple modules or clusters, that are significantly
positively or negatively correlated with genetic inactivation of the top six TSGs in MPM (Figure S1E).
Genes in the positively correlated modules indicate the abundance of the module-specified traits
conferred by individual TSG loss, while those in the negatively correlated ones indicate the attenuation.
Genes in the gray module are those that cannot be clustered.
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Figure 1. Major genetic alterations in The Cancer Genome Atlas (TCGA) MPM cohort. (A,B), 
Percentage (A) and overlap (B) of major (>10%) genetic alterations in The Cancer Genome Atlas 
(TCGA) malignant pleural mesothelioma (MPM) cohort (N = 81). (C), the association between the 
major genetic alterations (A) and the corresponding protein level in TCGA MPM cohort (N = 61). 
Protein array data were downloaded and reanalyzed from The Cancer Proteome Atlas (TCPA) 
database (https://tcpaportal.org/tcpa/). Of note, protein quantification data of LATS2 and SETD2 were 
not available in the TCPA database. Phospho-YAP (S127) and TAZ are two critical factors, indicating 
the activity of Hippo pathway. (D), Workflow of weighted gene correlation networks analysis (WGCNA). 
2.2. CDKN2A/2B 
CDKN2A/2B encodes three tumor suppressors, p16INK4a and p14ARF (by CDKN2A) and p15INK4b 
(by CDKN2B), that play critical roles in cell cycle regulation. Moreover, p16INK4a and p15INK4b are 
Figure 1. Major genetic alterations in The Cancer Genome Atlas (TCGA) MPM cohort. (A,B), Percentage
(A) and overlap (B) of major (>10%) genetic alterations in The Cancer Genome Atlas (TCGA) malignant
pleural mesothelioma (MPM) cohort (N = 81). (C), the association between the major genetic
alterations (A) and the corresponding protein level in TCGA MPM cohort (N = 61). Protein array
data were downloaded and reanalyzed from The Cancer Proteome Atlas (TCPA) database (https:
//tcpaportal.org/tcpa/). Of note, protein quantification data of LATS2 and SETD2 were not available in
the TCPA database. Phospho-YAP (S127) and TAZ are two critical factors, indicating the activity of
Hippo pathway. (D), Workflow of weighted gene correlation networks analysis (WGCNA).
2.2. CDKN2A/2B
CDKN2A/2B encodes three tumor suppressors, p16INK4a and p14ARF (by CDKN2A) and p15INK4b
(by CDKN2B), that play critical roles in cell cycle regulation. Moreover, p16INK4a and p15INK4b are
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functionally redundant by inhibiting cyclin-dependent kinase (CDK) 4/6 and cyclin D, and consequently
blocking cell cycle progression from G1 to S [13].
The correlation network showed that CDKN2A/2B loss in MPM was significantly positively
correlated with the green module (508 genes; correlation coefficient Pearson’s r = 0.55; p-value = 2 ×
10−7, followed by the yellow (543 genes; r = 0.34; p-value = 0.002), but negatively with the red (356 genes;
r = −0.36; p-value = 0.001) (Figure S1E). Pathway analyses (GO, KEGG, Reactome) revealed that the
green module enriched the genes involved in cell cycle regulation, particularly checkpoints and mitosis
(Figure 2A,B and Figure S2A), consistent with the function of CDKN2A/2B in cell-cycle regulation.
The yellow module significantly enriched the genes of extracellular matrix (ECM)-receptor interaction,
PI3K/AKT, and focal adhesion pathways (Figure 2C,D and Figure S2B,C). Interrogation of the RPPA
data revealed that MPM deficient in CDKN2A/2B had significantly higher levels of proteins involved in
the cell cycle (e.g., Cyclin B1, Cyclin E2, CDK1 (p-Y15), FOXM1) and PI3K (e.g., 4EBP1 and PKC-delta
(p-S664)) pathways, but decreased p16INK4a and PTEN (a negative regulator of PI3K) (Figure 2E),
further supporting our results.
The red module negatively correlated with CDKN2A/2B loss enriched genes of anti-viral type I
interferon (IFN-I, mainly IFN-α and IFN-β) signaling pathway, suggesting a link between CDKN2A/2B
inactivation and impaired IFN-I pathway (Figure 2E–G and Figure S2D). To explore the underlying
mechanisms, we analyzed co-occurring alterations in MPM samples, which revealed that CDKN2A
and genes of the IFN family were significantly co-deleted (Figure 2H), consistent with a recent study,
showing that defects in the IFN-I pathway mainly co-occur with CDKN2A loss [14].
We then analyzed intramodular connectivity, given that highly connected genes may serve as the
hub with core regulatory roles. The top 20 best-connected genes in the green module are KIF23, KIF4A,
KIF2C, HJURP, KIF18B, MYBL2, BUB1, NUF2, UBE2C, CDCA8, CKAP2L, PLK1, DLGAP5, CDC20,
TOP2A, DEPDC1, ANLN, CENPA, CDCA2, CEP55. Most of these genes regulate the mitotic process and
predict dismal prognosis in MPM (Figure S2E). Notably, the transcription factor MYBL2 is a central
regulator of cell survival, proliferation and differentiation in cancer [15], and PLK1 and TOP2A are
druggable by clinically advanced inhibitors. The top 20 best-connected genes in the yellow module
are COL5A1, VCAN, COL1A2, DACT1, FN1, CTHRC1, ITGA11, COL5A2, FAP, PODNL1, TGFB1I1,
COL1A1, MMP2, COL3A1, LTBP1, MATN3, CHST6, POSTN, COL16A1, SRPX2. Most of the genes are
involved in ECM and associated with the suppression of anticancer immunity [16,17]. Supporting this
notion, examining RPPA data revealed significantly decreased LCK, a key molecule in the selection
and maturation of developing T-cells [18] (Figure 2E). Moreover, MPM has a high ECM signature
compared to other solid tumors (Figure S3A), which predicts poor prognosis in patients (Figure S3B).
However, the genetic underpinning for the high ECM of MPM has been unclear. Our data showed
that the high ECM might be due to the high percentage (~46%) of MPM tumors with CDKN2A/2B
alterations. The top 20 most connective genes in the red module are OAS2, MX1, RSAD2, HERC6,
IFIT3, CMPK2, IFI6, ISG15, USP18, IFIT2, OASL, IFI44, MX2, DDX60, IFI44L, OAS1, LAMP3, CYP39A1,
IFIT1, RUFY4, with the vast majority involved in the IFN-I pathway.
Collectively, these results reveal cellular processes that may represent therapeutic vulnerabilities in
CDKN2A/2B deficient MPM. The enriched green and yellow modules indicate that CDKN2A/2B-mutant
MPM may benefit from the co-targeting of the G2/M checkpoint or mitosis (e.g., PLK1) with PI3K/AKT,
but might be associated with suppressive anticancer immunity due to high ECM. Oncolytic viral
immunotherapy, a novel anticancer strategy preferentially killing proliferating cancer cells but sparing
normal ones, might be particularly effective for the red module-marked subset, in which the IFN-I
pathway genes are often co-deleted.
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in the yellow module. (E), Volcano plot showing the significantly (adjusted p-value < 0.05) upregulated
(red) and downregulated (blue) proteins in malignant pleural mesothelioma (MPM) tum rs harboring
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(H), Genes significantly co-deleted with CDKN2A/2B in TCGA MPM samples. Data were downloaded
from cBioPortal (h tps://ww .cbioportal.org/). * p < 0.05. 2.3. BAP1.
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BAP1 has pleiotropic roles, ranging from the maintenance of genomic stability to the repair of
DNA double-strand breaks (DSBs) [19,20]. Our analysis showed that BAP1 alterations in MPM are
positively correlated with the red module only (r = 0.41; p-value = 2 × 10−4) that enriches the IFN-I
pathway (Figure 2F,G), and negatively correlated with CDKN2A/2B loss (Figure S1E). This finding
is supported by our recent study, showing that BAP1 is negatively correlated with the IFN-I gene
signature [21]. Thus, CDKN2A/2B deficiency plus BAP1 proficiency defines a unique MPM subset that
might particularly be sensitive to oncolytic viral immunotherapy.
2.3. NF2
NF2 is a plasma membrane protein binding to α-catenin and tight junctions to suppress cell
growth. NF2 loss deregulates multiple signal pathways, although a prevalent notion holds that the
Hippo pathway is central to the phenotype of NF2-mutant MPM.
Akin to CDKN2A loss, NF2 alterations are positively correlated with the green (r = 0.34; p-value
= 0.002) and the yellow (r = 0.26; p-value = 0.02) modules (Figure S1E), suggesting that NF2 might
regulate cell cycle [22,23] and PI3K/AKT/mTORC1 (yellow module) [24], in addition to the canonical
Hippo pathway. Supporting the notion, mining the public dataset that elaborates on protein-protein
interactions revealed that the proteins involved in the ribosome, tight junction, Hippo and DNA repair
are enriched in NF2-binding partners (Figure S4). The similarity between CDKN2A- and NF2-associated
gene expression can alternatively be because CDKN2A and NF2 alterations overlap in MPM (Figure 1B).
However, CDKN2A and BAP1 deficiency co-occurs at an even greater extent (Figure 1B) but rewires
different gene networks (Figure 2) argues against this possibility.
Thus, like CDKN2A/2B, the genetic inactivation of NF2 deregulates cell cycle, ECM and PI3K/AKT
pathways, which prioritizes the co-targeting of the G2/M checkpoint/mitosis and PI3K/AKT pathway
for NF2-altered MPM.
2.4. TP53
TP53 mutations are negatively correlated with the purple module (125 genes; r = −0.37; p-value =
9 × 10−4), to a less extent with the turquoise (1143 genes; r = −0.29; p-value = 0.01) and the green-yellow
(108 genes; r = −0.27; p-value = 0.02), but positively with the salmon (57 genes; r = 0.23; p-value = 0.04),
implying that TP53 mutations deregulate multiple biological processes in MPM (Figure S1E). Notably,
the turquoise is also significantly correlated with LATS2 alterations (Figure S1E); we therefore focused
on the purple and green-yellow module in the context of TP53 mutations.
The purple module enriches genes of adipocyte differentiation/lipid metabolism, suggesting that
TP53-mutant MPM might have attenuated activity of the processes (Figure 3A,B and Figure S5A) and
benefit from differentiation therapy, e.g., peroxisome proliferator-activated receptor (PPAR) activator
(Figure S5A). Supporting this notion, PPAR activator has been shown to promote the differentiation of
mesenchymal therapy-resistant cancer cells to adipocytes [25]. Furthermore, the green-yellow module
negatively correlated with TP53 mutations enrich genes involved in lung epithelial cell differentiation
(Figure 3C,D and Figure S5B), and the positively correlated salmon module enriches for genes of the
neuronal system (Figure 3E,F). However, the marginal significance (p-value = 0.04) limits the value of
this module.
The top 20 best-connected genes within the purple module are AQP7, PLIN1, ADIPOQ, TUSC5,
CIDEA, THRSP, PLIN4, CIDEC, C14orf180, AQP7P1, CD300LG, C6, LIPE, LEP, NTRK2, SLC7A10,
KCNIP2, GPD1, PDK4, and LPL, among which chemical agonists for PDK4, PRKAR2B and LPL are
available. The top 20 best-connected genes of the green-yellow module include PDK4, TUSC5, LIPE,
CIDEC, KCNIP2, CTSG, THRSP, CIDEA, AQP7P1, CD300LG, C7, C6, FREM1, THSD7B, MS4A2, TPSB2,
C14orf180, FAM107A, TPSAB1, and TNMD.
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Figure 3. Enrichment analyses of genes significantly correlated with MPM tumors with TP53 alterations.
(A,E), Significantly enriched Reactome pathways based on genes in the purple (A,B), green-yellow
(C,D) and salmon (E,F) modules. Cnetplots in (B), (D) and (F) listed genes in the enriched Reactome
pathways (A, C and E, respectively).
2.5. SETD2
SETD2 is a histone-modifying enzyme responsible for trimethylation of the lysine 36 residue
on Histone 3 (H3K36me3) in humans. Impaired H3K36me3 causes aberrant gene regulation and
chromosomal instability [26].
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MPM with SETD2 alterations is exclusively abundant (r = 0.25; p-value = 0.03) in the turquoise
module, consisting of 1143 genes, with functions spanning from neuronal biology and receptor tyrosine
kinases (particularly EGFR family) to the potassium channel, the Hippo and Wnt (Figure 4A–C).
The Hippo and Wnt pathways are tumor-suppressive, precluding the potential as therapeutic targets.
However, our results suggest that targeting EGFR might be a novel strategy for SETD2-altered MPM
(Figure 4A,B).
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Figure 4. Enrichment analyses of genes significantly correlated with MPM tumors with SETD2
alterations. (A,C) Top 10 significantly enriched Reactome (A,B) and Kyoto Encyclopedia of Genes
and Genomes (KEGG) (C) pathways based on genes in the turquoise module. Cnetplot in (B) listed
genes in the enriched Reactome pathways (A). (D) Volcano plot showing the significantly (adjusted
p-value < 0.05) upregulated (red) and downregulated (blue) proteins in malignant pleural mesothelioma
(MPM) tumors with SETD2 alterations (versus wild-type), based on The Cancer Genome Atlas (TCGA)
MPM cohort (N = 61). Data were downloaded and reanalyzed from The Cancer Proteome Atlas
(TCPA) database (https://tcpaportal.org/tcpa/). (E) Box-and-whisker plots show the extent of correlation
between cytotoxic effects of each compound and with CDH1 (encoding E-cadherin) mRNA level,
across 670 solid cancer cell lines. The y-axis indicates z scored Pearson’s correlation coefficients; line,
median; box, 25–75th percentile; whiskers, 2.5th and 97.5th percentile expansion; Here, only significantly
(p < 0.05) correlated inhibitors were shown (in red dots). Labeled dots indicated the most negatively
correlated drugs.
Cancers 2020, 12, 2310 9 of 20
Genetic/molecular co-occurrence in tumor samples implies that progression to malignancy is a
consequence of cooperative genetic/molecular dysregulations. Indeed, genetic alterations in EGFR
and SETD2 frequently co-occur in glioma [27] and TCGA pan-cancer cohort (Figure S6), supporting
the notion that co-occurring EGFR and SETD2 alterations cooperate to promote tumor progression,
and that SETD2-mutant cancer may evolve a dependency on EGFR signaling. To further confirm
the link between SETD2 alterations and sensitivity to EGFR inhibition, we performed integrated
analyses of proteomic (RPPA) and drug sensitivity data, which revealed that E-cadherin is significantly
upregulated in SETD2-altered MPM (Figure 4D) and the expression of CDH1 (encoding E-cadherin) is
most negatively correlated with sensitivity to various EGFR inhibitors (Figure 4E). Of note, the red
module, abundant in the IFN-I signature and positively correlated with BAP1 alterations, is also
positively correlated with SETD2 mutations in MPM. This can be explained by considerably co-occurring
BAP1 and SETD2 mutations, as 8 of 11 SETD2-altered MPM also have aberrant BAP1 (Figure 1B).
RPPA analysis confirmed significantly downregulated BAP1 in SETD2-altered MPM (Figure 4D).
The top 20 best-connected genes in the turquoise module are KLK11, CCDC64, CARNS1, CGN,
BNC1, CLDN15, COBL, PARD6B, PLLP, PRR15, IGSF9, PRR15L, ANXA9, SELENBP1, PDZK1IP1,
TGM1, SOX6, HOOK1, MSLN, NRG4. One of the hub genes in this module is MSLN, encoding
mesothelin, a well-characterized biomarker for mesothelial tissue, and commonly overexpressed in
epithelial mesotheliomas.
2.6. LATS2
At the heart of the Hippo pathway stands a core kinase cassette: MST1/2, LATS1/2, and adaptor
proteins SAV1, MOB1A/B, which converges at LATS1/2-dependent phosphorylation of Yes-associated
protein (YAP) and transcriptional co-activator with TAZ.
LATS2 alterations show a negative correlation with the turquoise module (Figure 2, r = −0.45;
p-value = 4 × 10−5), which is opposite to SETD2 alterations (positively correlated with the turquoise),
but expected, in that genes involved in the Hippo and tight junction pathways are enriched in the
turquoise module. Importantly, LATS2 alterations in MPM are exclusively positively correlated (r = 0.33;
p-value = 0.004) with the brown module (Figure S1E and Figure 5A), which significantly enriches for
genes involved in immunoregulation (Figure 5B,C). These results suggest an immunoregulatory role
beyond the canonical Hippo pathway by LATS2 and a rationale of immunotherapy for LATS2-altered
MPM. Supporting the notion, PD-L1 (encoded by CD274) is the most significantly upregulated
protein in LATS2-mutant MPM (Figure S7A), and LATS1/2 deletion has recently been shown to
enhance anti-tumor immune responses [28]. Strikingly, a retrospective analysis of patients after being
treated with immune checkpoint blockade showed that mutations of LATS1/2, rather than of NF2,
predict significantly better survival (Figure 6A and Figure S7B).
The top 20 best-connected genes in the brown module are LCK, CD3E, IL2RG, SLAMF6,
CD2, CD3D, SIT1, SH2D1A, CXCR3, TIGIT, TRAT1, CD6, GZMK, CD247, SIRPG, CD27, ZAP70,
TBC1D10C, CD96, CD5. Of these, CD3E, IL2RG, CD2, CD3D, CD6, CD247, CD5, ITK, and CD3G are
pharmacologically tractable.
Protein domains are important functional units and crucial for deconvolution of drug targets;
we thus explored functional domains of the proteins encoded by the top 20 hub genes. Using SMART
and PFAM protein fomains, we found that immunoreceptor tyrosine-based activation motif and Src
homology 2 (SH2) domains are significantly enriched (false discovery rate < 0.05) in the hub proteins
(Figure S7C). By correlating drug sensitivity with the gene expression of cancer cell lines (n = 670),
we identified Dasatinib, a potent Abl/Src inhibitor, with the efficacy negatively correlated with several
immune biomarkers (CD274, CD47, PDCD1LG2), that are preferentially expressed by cancer cells
(Figure 6B). These results suggest that a role by LATS2 in cancer immunity and the potential of
Dasatinib to target LATS2-altered MPM.
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Figure 5. Enrichment analyses of genes significantly correlated with MPM tumors with LATS2
alterations. (A), Hierarchical clustering dendrogram of module eigengenes (labeled by their colors) and
the sample trait (genetic alterations). Heatmap plot of the adjacencies in the eigengene network. In the
heatmap, each row and column corresponds to one module eigengene (labeled by colors) or the trait.
In the heatmap, green color indicates a negative correlation, while red represents a positive correlation.
(B,C), Top 10 significantly enriched GO (biological process, BP), Kyoto Encyclopedia of Genes and
Genomes (KEGG) and Reactome (C) pathways based on genes in the brown module. Cnetplot in C
listed genes in the enriched Reactome pathways (B).
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Notably, Dasatinib is the most negatively correlated drug. (C,D) the median inhibitory concentration 
(IC50) values of a panel of MPM cell lines treated with Dasatinib (72 h). MPM cells seeded in triplicate 
at 96-well plates were drugged 24 h later, over a 12-point concentration range (two-fold dilution). 
DMSO-treated cells were used as control. IC50 was determined using GraphPad Prism 7. IC50 values 
of Dasatinib in three MPM cell lines (H28, MSTO-211H, H2052) cultured in 2D and 3D were 
compared. * p < 0.05 by Welch’s t-test. N = 3 biological replicates. In D, the genetic annotations of MPM 
cell lines (C) were shown. 
The top 20 best-connected genes in the brown module are LCK, CD3E, IL2RG, SLAMF6, CD2, 
CD3D, SIT1, SH2D1A, CXCR3, TIGIT, TRAT1, CD6, GZMK, CD247, SIRPG, CD27, ZAP70, 
i re . Identify Dasatinib as a promising therapeutic drug for PM with LATS2 al erations.
(A) LATS1/2 mutational statu is associated with sign ficantly improved overa l i l cancer
patie ts after i une checkpoint blockage. i tri ti f s l t ( ri r s.
left panel), cancer type (middle panel) and drug type (anti-CTLA4; anti-PD1/PDL1; right panel) betwe n
LATS1/2-mutant and wild-type cancer. (B) Box-and-whisker plots show th exten of correlation between
cytotoxic effec s of Dasatinib and with several well-characterized immune markers (PDL1, PDL2,
CD47), preferentially expressed by ca cer cells. The y-axis i dicat s z scored Pearson’s correlation
coefficients; lin , median; box, 25–75th perc ntile; whiskers, 2.5th and 97.5th percentile expansion; Here,
only significantly (p < 0.05) correlated inhibitors were shown (in red dots). Notably, Dasatinib is the
m st negatively correlated drug. (C,D) the median inhibitory concentration (IC50) values f a panel f
MPM cell lines treated with Dasatinib (72 h). MPM cells seeded in triplicate at 96-well plates were
drugged 24 h later, over a 12-point concentration range (two-fold dilution). DMSO-treated cells were
used as control. IC50 was determined using GraphPad Prism 7. IC50 values of Dasatinib in three MPM
cell lines (H28, MSTO-211H, H2052) cultured in 2D and 3D were compared. * p < 0.05 by Welch’s t-test.
N = 3 biological replicates. In D, the genetic annotations of MPM cell lines (C) were shown.
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As preclinical proof of the concept, we found that LATS1/2-altered MPM cells exhibited the highest
sensitivity to Dasatinib (Figure 6C,D). Importantly, the LATS1/2-altered MPM cells cultured in 3D retain
a high sensitivity to Dasatinib (Figure 6C). Surprisingly, the mutational status of NF2, an upstream
factor of LATS1/2 in the Hippo pathway, appeared not to predict the sensitivity to Dasatinib, which may
suggest that NF2 and LATS1/2 have distinct and uncoupled functions in MPM. Further supporting our
finding, Dasatinib was reported to show durable anticancer effects by promoting anti-tumor T cell
responses, besides direct targeting of Abl/Src [29,30].
Finally, by analyzing RPPA data, we identified several antioxidant and anti-ferroptotic proteins,
e.g., TFRC, GP6D, and PRDX1, that are significantly enriched in LATS2-altered MPM (Figure S7) [31].
In line with this observation, MPM with the aberrant Hippo pathway was reported to be susceptible to
ferroptosis induction [32].
These results uncover an unexpected role for LATS2 in modulating immune contexture, suggesting
a rationale for Dasatinib to treat LATS2-mutant MPM. Our data also argue that LATS2 and NF2 may
exert distinct roles in MPM, at odds with the long-held assumption that they act as tumor suppressors
through the Hippo pathway.
3. Discussion
Cancer patients vary in prognosis and response to therapy due to tumor heterogeneity [33,34],
highlighting the need for personalized treatment. Unlike many other solid tumors, MPM is characterized
by a pharmacologically intractable abnormal tumor genome, mainly TSGs, for which targeted therapy
has been poorly established. In this study, we presented, for the first time, a systematic analysis of
biochemical networks and associated vulnerabilities induced by the functional loss of TSGs in MPM,
which not only sheds light on the mechanisms of MPM biology but also provides a framework of
biomarker-guided targeted therapy in MPM (Figure S8).
3.1. CDKN2A/2B and NF2
An important finding of this study is that CDKN2A and NF2 loss leads to similar changes in
cellular pathways in MPM. Despite the evidence for targeting PI3K/AKT/mTOR pathway in MPM
subsets [3,35–38], whether the deregulation of the pathway is associated with specific genetic events is
unclear. Our results reveal the molecular underpinning of CDKN2A and NF2 deficiencies, and further
suggest therapeutic options for these MPM subsets. As p16INK4a (product of CDKN2A) inhibits
CDK4/6 [13], CDK4/6 activation upon CDKN2A loss renders CDKN2A-deficient MPM particularly
vulnerable to CDK4/6 inhibitors [36,39], and co-targeting CDK4/6 and PI3K/AKT/mTOR induce
synergistic anti-MPM effects [36]. PI3K/mTOR inhibitors as monotherapy failed in unselected MPM
patients [7], highlighting the importance of biomarker-guided stratification in future clinical trials.
Oncolytic viral immunotherapy shows promises in MPM [40], partly due to the special location of
the malignancy that facilitates viral administration. We showed that IFN-I pathway genes are often
co-deleted with CDKN2A, suggesting a rational by oncolytic viral immunotherapy for CDKN2A-altered
MPM, which is supported by a recent report [14]. As CDKN2A/2B loss is widely used in pathological
diagnosis to distinguish MPM from benign pleural lesions, analyzing the mutations of IFN-I–related
genes will improve MPM diagnosis and patient stratification.
MPM has a high ECM signature, which may drive immunotherapy resistance [16,17]. Here,
we provided evidence that high ECM in MPM is mainly attributable to CDKN2A/2B and NF2 deficiency,
that accounts for ~55.6% (45 of 81) of MPM cases (Figure 1B).
3.2. BAP1
BAP1 loss is frequent in MPM, renal cell carcinoma, peritoneal mesothelioma, and uveal
melanoma [41]. Given the role of BAP1 in the maintenance of genomic stability, the association
between BAP1 mutations and sensitivity to PARP1-targeted therapy has been demonstrated in the
chicken model of DT40 cells [19]. However, we and others have recently shown that BAP1 mutations
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cannot precisely predict the response to PARP1-targeted therapy in MPM [20,42]. In addition,
BAP1 status has been shown to determine the sensitivity to Gemcitabine treatment in MPM [43,44].
Here, BAP1 alterations show significant abundance in IFN-I pathway only, consistent with our
finding that BAP1 is negatively correlated with the IFN-I signature in MPM [21]. Our data suggest
that CDKN2A deficiency and BAP1 proficiency should be considered to stratify MPM for oncolytic
viral immunotherapy.
3.3. TP53
Mutant p53 has been proposed to drive metabolic reprogramming, thereby promoting cancer
progression [45–48]. Our data reveal a potential role for TP53 mutation in lipid metabolism,
by deregulating the PPAR signaling pathway. Supporting our finding, p53 interacts with PPAR-γ
co-activator 1α (PGC-1α) [45–47], and PPAR activator promotes the differentiation of mesenchymal
therapy-resistant breast cancer cells [25]. These results warrant further studies to test differentiation
therapy for TP53-mutant MPM.
Notably, synthetic lethal targets with p53 inactivation have been investigated [49–51]. In particular,
MDM2, a nuclear E3 ubiquitin ligase that binds and targets p53 for proteasomal degradation, is detected
in 21.3% of clinical MPM samples, and its expression is significantly associated with poor survival [52].
To restore p53 function, several small molecules, such as the Nutlin-like drugs that disrupt MDM2/p53
interaction, have been tested in MPM [53–55]. Moreover, we and others have shown that the
inactivation of CDKN2A/2B and TP53 is associated with an increased dependence on the G2/M
checkpoint, which represents a targetable vulnerability in MPM [56,57].
3.4. SETD2
We showed that SETD2 might have roles beyond histone modifications. Of note, RTKs, particularly
EGFR members (HER1 (EGFR, ERBB1), HER2 (NEU, ERBB2), HER3 (ERBB3), and HER4 (ERBB4))
were exclusively enriched in SETD2-altered MPM, suggesting the potential of pan-EGFR inhibitors for
this MPM subset. Indeed, co-mutant EGFR and SETD2 are common in glioma and pan-cancer [27],
suggesting that SETD2-mutant cancer might have evolved a unique dependence on EGFR signaling.
EGFR is not mutated, but overexpressed in MPM [58–60]. A previous study showed that
MPM expressed EGFR (79.2%), ErbB4 (49.0%) and HER2 (6.3%), but lacked ErbB3 [61]. In line with
this, anti-HER-2 antibody synergizes with cisplatin in a subset of MPM cell lines [62]. However,
the first-generation EGFR/ERBB1 inhibitor erlotinib [9] and gefitinib [8] show no clinical benefit,
suggesting that pan-EGFR inhibitors might be necessary. To be noted, EGFR and other RTKs (MET,
AXL) have been demonstrated to contribute to the activation of the downstream PI3K/AKT/mTOR
in MPM [35], and the targeting PI3K/AKT/mTOR pathway, alone or in combination with other
agents, have been investigated in MPM [7,36–38]. We showed that E-Cadherin is overexpressed
in SETD2-altered MPM and predicts the sensitivity to EGFR-targeted therapies. Our finding that
E-cadherin is significantly negatively correlated with EGFR inhibitor efficacy prioritizes the need for
biomarker-driven selection and pan-EGFR inhibitors that target ERBB2/3/4 as well.
3.5. LATS2
LATS1/2 are key players of the Hippo pathway, but only LATS2 is frequently mutated in MPM.
We identified the significant enrichment of immunoregulatory pathways in LATS2-mutant MPM,
suggesting an unanticipated role for LATS2 in immunoregulation. Supporting our finding, LATS1/2
can suppress cancer immunity, and their deletion improves tumor immunogenicity by enhancing
anti-tumor immune responses [28]. These results support a rationale of immunotherapy to target
LATS2-altered MPM, although how LATS1/2 modulates the immune response awaits further studies.
Immunotherapy shows promises in MPM, but with low and heterogeneous response rates [63,64],
arguing for biomarker-guided stratifications of MPM subsets responsive to immunotherapies. Our data
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suggest that LATS2 mutational status might be a critical factor in selecting MPM patients who can
benefit from immunotherapies.
Strikingly, our study identified Dasatinib, a clinically approved RTK inhibitor, as a promising
therapeutic for LATS2-altered MPM. Dasatinib shows the potential to modulate anticancer immunity
(Figure 6B), and selectively impairs LATS2-altered MPM cells (Figure 6C), in line with the evidence
that Dasatinib enhances anti-PDL1 efficacy in cancer [30]. These data suggest a rationale, by combining
Dasatinib with immune checkpoint blockades to treat LATS2-altered MPM. Indeed, LATS2 mutations
are associated with beneficial survival in immunotherapy-treated patients (Figure 6A), but Dasatinib
as monotherapy failed in unselected MPM patients [6,65], supporting the use of LATS2 mutational
status for patient stratification in clinical trials with Dasatinib.
Finally, we reveal a significant enrichment of proteins regulating ferroptosis in LATS2-mutant
MPM, but not in those with NF2 alterations, which is at odds with a recent report, showing that
aberrant NF2-Hippo pathway is selectively susceptible to ferroptosis induction [32]. The observation
that NF2 and LATS2 likely play different roles in MPM is supported by several lines of evidence. First,
LATS2 rather than NF2 alterations are associated dysregulated YAP and TAZ (Figure 1C); secondly,
LATS2- and NF2-mutant tumors show strikingly different enrichment of gene and protein signatures
(Figures S1E and S7 and Figure 5); thirdly, Dasatinib selectively impairs LATS2- but not NF2-altered
MPM (Figure 6); fourthly, LATS1/2 mutations but not NF2 alterations predict better survival in patients
after immune checkpoint blockade therapy (Figure 6A and Figure S7B). Together, our data suggest that
LATS2 and NF2 might have distinct roles in MPM, despite the long-held notion that both function
through the Hippo pathway.
4. Materials and Methods
4.1. WGCNA and Function Enrichment Analyses
To identify the gene expression profiling associated with the major genetic alterations in MPM,
The R package “WGCNA” was applied to the RNA-sequencing data retrieved from TCGA MPM cohort.
In WGCNA, genes are clustered based on co-expression patterns to construct a gene co-expression
network, which was transformed into the adjacency matrix and then topological overlap matrix
(TOM) [12]. According to the TOM-based dissimilarity measure, genes were grouped into different
modules (clusters) using the dynamic tree cut algorithm. For each module, the module eigengene
(ME) was calculated; the first principal component representative of the module. The ME values were
correlated with sample traits defined by specific genetic alterations in MPM samples. Here, we set the
soft-thresholding power at 5 (scale-free R2 = 0.86), cut height at 0.25, and minimal module size to 30,
to identify key modules. The module significantly correlated with sample traits was selected to explore
its biological functions, such as gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes
(KEGG) and reactome pathway enrichment analyses, using the R package “clusterprofiler” [66].
Hub genes were defined as top 20 intramodular connected genes.
4.2. Cell Viability Assay
All normal human mesothelial cells Met-5A (MeT-5A, RRID: CVCL_3749), MPM cell lines H28
(NCI-H28, RRID: CVCL_1555), H2452 (NCI-H2452, RRID: CVCL_1553), and H2052 (NCI-H2052,
RRID: CVCL_1518) were obtained from ATCC (American Type Culture Collection, Manassas, VA,
USA) [67]. MPM cell lines MESO-1 (ACC-MESO-1, RRID: CVCL_5113) and MESO-4 (ACC-MESO-4,
RRID: CVCL_5114) were obtained from RIKEN Cell Bank (Ibaraki, Japan). MPM cell lines MSTO-211H
(RRID: CVCL_1430) and JL-1 (RRID: CVCL_2080) were purchased from DSMZ (German Collection of
Microorganisms and Cell Cultures, Brunswick, Germany). A primary MPM cell culture (BE261T) was
established from surgically resected tumors of a 67-year-old male patient, using the same protocol as
described in [67] and used for short-term studies (up to eight passages in vitro). The human study
was performed under the auspices of protocols approved by institutional review board (KEK number:
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042/15), and informed consent was obtained from patients. Cells were cultured in RPMI-1640 medium
(Cat. #8758; Sigma-Aldrich, St. Louis, MO, USA), supplemented with 10% fetal bovine serum/FBS (Cat.
#10270-106; Life Technologies, Grand Island, NY, USA) and 1% penicillin/streptomycin (P/S) solution
(Cat. #P0781, Sigma-Aldrich, St. Louis, MO, USA). For 3D culture, cells were cultured in ultra-low
attachment plate (Sigma-Aldrich, #CLS3474-24EA) with FBS-free RPMI-1640 medium supplemented
with EGF (20 ng/mL; Cat. #PHG0311; Thermo Fisher Scientific (Waltham, MA, USA), bFGF (20 ng/mL;
Cat. #PHG6015; Thermo Fisher Scientific), 4µg/mL insulin (Cat. #I9278; Sigma-Aldrich), 1× B-27 (Cat.
#17504044; Thermo Fisher Scientific), 1% P/S. All human cell lines have been authenticated using
STR profiling within the last three years, and are confirmed free from mycoplasma contamination
(Microsynth, Bern, Switzerland).
MPM cells seeded in triplicate at 96-well plates (for 2D: 1000–1500 cells/well in tissue-culture
treated plate (Corning, #353072); for 3D: 4000–5000 cells/well in ultra-low attachment plate) were
drugged 24 h later, over a 12-point concentration range (two-fold dilution), with DMSO as vehicle.
Cell viability was determined 72 h post-treatment by the Acid Phosphatase Assay Kit (ab83367;
Abcam) [68]. The median inhibitory concentration (IC50) was calculated using GraphPad Prism 7.
4.3. Public Databases
RNA-sequencing data of MPM samples (n = 87) were downloaded from TCGA (https://portal.gdc.
cancer.gov/), in which 81 samples were provided with genetic alterations data. Normalized level 4
data of reverse phase protein array (RPPA) were downloaded from The Cancer Proteome Atlas (TCPA)
database (https://tcpaportal.org/tcpa/) [69], which quantified 218 proteins in 61 out of the 87 MPM
samples in TCGA. R packages “limma” and “edgeR” were used to normalize the data and identify the
differential gene or protein expression, respectively [70]. Protein-interacting data were downloaded
from Agile Protein Interactomes DataServer (http://cicblade.dep.usal.es:8080/APID/init.action) [71],
and co-occurring analysis data were downloaded from cBioPortal (https://www.cbioportal.org/).
Processed drug (n = 481) screening and gene expression data across solid cancer cell lines (n = 659)
were downloaded and reanalyzed from a published study [11]. Fisher’s z-transformation was applied
to the correlation coefficients to adjust for (normalize) variations in cancer cell line numbers across
small molecules and cell lineages. Genetic and survival data of patients after immunotherapies
(anti-PD1/PDL1, anti-CTLA4) were from TMB and immunotherapy (MSKCC) cohort in cBioPortal [72].
4.4. Survival Analysis
Survival analysis was performed using “survminer” and “survival” R packages. Tumor samples
within the TCGA MPM cohort were divided into two groups, based on each hub gene’s best-separation
cut-off value to plot the Kaplan–Meier survival curves.
4.5. ECM Gene Signature
The extracellular matrix (ECM)/stromal gene signature was scored as the sum of an ECM/stromal
gene set (VCAN, FAP, POSTN, FBLN1, COL1A1, PDPN, THY1, CSPG4, IL6, TGFB1, HGF, SERPINE1).
The gene list was curated based on previous studies across different cancer lineages [16,17].
4.6. Statistical Analysis
Data were presented as mean ± SD, with the indicated sample size (n) representing biological
replicates. Gene expression and survival data derived from the public database, as well as the correlation
coefficient, were analyzed using R (version 3.6.0). p < 0.05 was considered statistically significant.
5. Conclusions
Overall, we report the systematic identification of biochemical networks and therapeutic potential
linked with aberrant TSGs, which provides a framework for biomarker-guided precision oncology
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for MPM subsets. Our work warrants further studies that verify the drug vulnerabilities and the
stratification approaches for future clinical trials.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/8/2310/s1,
Figure S1: Weighted gene correlation network analysis (WGCNA) reveal gene modules linked with major
genetic alterations in MPM; Figure S2: Pathway enrichment analyses of the genes significantly correlated with
CDKN2A/2B loss; Figure S3: MPM has a high extracellular matrix (ECM) gene signature; Figure S4: Pathway
enrichment analyses of the genes significantly correlated with NF2 alterations; Figure S5: Pathway enrichment
analyses of the genes significantly correlated with TP53 mutations; Figure S6: Mutually exclusive and co-occurring
analyses of STED2 and EGFR family genes across TCGA pan-cancer solid tumors; Figure S7: LATS2-altered MPM
tumors enrich for the immune-regulatory signature; Figure S8: Tumor suppressor genes (TSGs)-guided precision
oncology in MPM.
Author Contributions: Conceptualization, H.Y. and R.-W.P. Methodology, H.Y., D.X., Z.Y. Formal Analysis, H.Y.
Investigation, H.Y., D.X., Z.Y. Data Curation, F.Y., H.Z., R.A.S., R.-W.P. Writing—Original Draft Preparation,
H.Y. Writing—Review and Editing, all authors. Supervision, R.A.S., R.-W.P. Project Administration, R.A.S.,
R.-W.P. Funding Acquisition, H.Y., Z.Y., R.-W.P. All authors have read and agreed to the published version of
the manuscript.
Funding: This work was supported by grants from Swiss Cancer League/Swiss Cancer Research Foundation
(#KFS-4851-08-2019; to R.-W.P.), Swiss National Science Foundation (SNSF; #310030_192648; to R.-W.P.) and PhD
fellowships from China Scholarship Council (to H.Y. and Z.Y.).
Acknowledgments: This study used TCGA Program database. The interpretation and reporting of these data are
the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute.
Conflicts of Interest: The authors have declared no conflicts of interest.
References
1. Mutti, L.; Peikert, T.; Robinson, B.W.S.; Scherpereel, A.; Tsao, A.S.; De Perrot, M.; Woodard, G.A.; Jablons, D.M.;
Wiens, J.; Hirsch, F.R.; et al. Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
J. Thorac. Oncol. 2018, 13, 1269–1283. [CrossRef] [PubMed]
2. Vogelzang, N.J.; Rusthoven, J.J.; Symanowski, J.; Denham, C.; Kaukel, E.; Ruffié, P.; Gatzemeier, U.; Boyer, M.;
Emri, S.; Manegold, C.; et al. Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin
Alone in Patients with Malignant Pleural Mesothelioma. J. Clin. Oncol. 2003, 21, 2636–2644. [CrossRef]
[PubMed]
3. Bueno, R.; Stawiski, E.W.; Goldstein, L.D.; Durinck, S.; De Rienzo, A.; Modrusan, Z.; Gnad, F.; Nguyen, T.T.;
Jaiswal, B.S.; Chirieac, L.R.; et al. Comprehensive genomic analysis of malignant pleural mesothelioma
identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 2016, 48, 407–416. [CrossRef]
[PubMed]
4. Hmeljak, J.; Sanchez-Vega, F.; Hoadley, K.A.; Shih, J.; Stewart, C.; Heiman, D.; Tarpey, P.; Danilova, L.; Drill, E.;
Gibb, E.A.; et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov.
2018, 8, 1548–1565. [CrossRef] [PubMed]
5. Guo, G.; Chmielecki, J.; Goparaju, C.; Heguy, A.; Dolgalev, I.; Carbone, M.; Seepo, S.; Meyerson, M.; Pass, H.I.
Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in
Malignant Pleural Mesothelioma. Cancer Res. 2014, 75, 264–269. [CrossRef]
6. Dudek, A.Z.; Pang, H.; Kratzke, R.A.; Otterson, G.A.; Hodgson, L.; Vokes, E.E.; Kindler, H.L.; Cancer and
Leukemia Group B. Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma
(Cancer and Leukemia Group B 30601): A Brief Report. J. Thorac. Oncol. 2012, 7, 755–759. [CrossRef]
7. Ou, S.-H.I.; Moon, J.; Garland, L.L.; Mack, P.C.; Testa, J.R.; Tsao, A.S.; Wozniak, A.J.; Gandara, D.R.
SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural
mesothelioma (MPM). J. Thorac. Oncol. 2015, 10, 387–391. [CrossRef]
8. Govindan, R. Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and
Leukemia Group B. Clin. Cancer Res. 2005, 11, 2300–2304. [CrossRef]
9. Garland, L.L.; Rankin, C.; Gandara, D.R.; Rivkin, S.E.; Scott, K.M.; Nagle, R.B.; Klein-Szanto, A.J.; Testa, J.R.;
Altomare, D.A.; Borden, E.C. Phase II Study of Erlotinib in Patients with Malignant Pleural Mesothelioma:
A Southwest Oncology Group Study. J. Clin. Oncol. 2007, 25, 2406–2413. [CrossRef]
Cancers 2020, 12, 2310 17 of 20
10. Ding, H.; Zhao, J.; Zhang, Y.; Yu, J.; Liu, M.; Li, X.; Xu, L.; Lin, M.; Liu, C.; He, Z.; et al. Systematic Analysis of
Drug Vulnerabilities Conferred by Tumor Suppressor Loss. Cell Rep. 2019, 27, 3331–3344.e6. [CrossRef]
11. Rees, M.G.; Seashore-Ludlow, B.; Cheah, J.H.; Adams, D.J.; Price, E.V.; Gill, S.; Javaid, S.; Coletti, M.E.;
Jones, V.L.; Bodycombe, N.E.; et al. Correlating chemical sensitivity and basal gene expression reveals
mechanism of action. Nat. Methods 2015, 12, 109–116. [CrossRef] [PubMed]
12. Langfelder, P.; Horvath, S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinform.
2008, 9, 559. [CrossRef] [PubMed]
13. Zhao, R.; Choi, B.Y.; Lee, M.-H.; Bode, A.M.; Surh, Y.-J. Implications of Genetic and Epigenetic Alterations of
CDKN2A (p16(INK4a)) in Cancer. EBioMedicine 2016, 8, 30–39. [CrossRef]
14. Delaunay, T.; Achard, C.; Boisgerault, N.; Grard, M.; Petithomme, T.; Chatelain, C.; Dutoit, S.; Blanquart, C.;
Royer, P.-J.; Minvielle, S.; et al. Frequent Homozygous Deletions of Type I Interferon Genes in Pleural
Mesothelioma Confer Sensitivity to Oncolytic Measles Virus. J. Thorac. Oncol. 2020, 15, 827–842. [CrossRef]
[PubMed]
15. Musa, J.; Aynaud, M.-M.; Mirabeau, O.; Delattre, O.; Grünewald, T.G.P. MYBL2 (B-Myb): A central regulator
of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017, 8, e2895.
[CrossRef]
16. Mushtaq, M.U.; Papadas, A.; Pagenkopf, A.; Flietner, E.; Morrow, Z.; Chaudhary, S.G.; Asimakopoulos, F.
Tumor matrix remodeling and novel immunotherapies: The promise of matrix-derived immune biomarkers.
J. Immunother. Cancer 2018, 6, 65. [CrossRef]
17. Chakravarthy, A.; Khan, L.; Bensler, N.P.; Bose, P.; De Carvalho, D.D. TGF-β-associated extracellular matrix
genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat. Commun. 2018,
9, 4692. [CrossRef]
18. Bommhardt, U.; Schraven, B.; Simeoni, L. Beyond TCR Signaling: Emerging Functions of Lck in Cancer and
Immunotherapy. Int. J. Mol. Sci. 2019, 20, 3500. [CrossRef]
19. Yu, H.; Pak, H.; Hammond-Martel, I.; Ghram, M.; Rodrigue, A.; Daou, S.; Barbour, H.; Corbeil, L.; Hébert, J.;
Drobetsky, E.; et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.
Proc. Natl. Acad. Sci. USA 2013, 111, 285–290. [CrossRef]
20. Yang, H.; Xu, D.; Gao, Y.; Schmid, R.A.; Peng, R.-W. The Association of BAP1 Loss-of-Function with the
Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy. J. Thorac. Oncol.
2020, 15, e88–e90. [CrossRef]
21. Yang, H. Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in
RAS-Mutant Lung Cancer. J. Thorac. Oncol. 2020, 15, e58–e59. [CrossRef] [PubMed]
22. Xiao, G.-H.; Gallagher, R.; Shetler, J.; Skele, K.; Altomare, D.A.; Pestell, R.G.; Jhanwar, S.; Testa, J.R. The NF2
Tumor Suppressor Gene Product, Merlin, Inhibits Cell Proliferation and Cell Cycle Progression by Repressing
Cyclin D1 Expression. Mol. Cell. Biol. 2005, 25, 2384–2394. [CrossRef] [PubMed]
23. Shi, Y.; Bollam, S.R.; White, S.M.; Laughlin, S.Z.; Graham, G.T.; Wadhwa, M.; Chen, H.; Nguyen, C.; Vitte, J.;
Giovannini, M.; et al. Rac1-Mediated DNA Damage and Inflammation Promote Nf2 Tumorigenesis but Also
Limit Cell-Cycle Progression. Dev. Cell 2016, 39, 452–465. [CrossRef] [PubMed]
24. López-Lago, M.A.; Okada, T.; Murillo, M.M.; Socci, N.; Giancotti, F.G. Loss of the Tumor Suppressor Gene
NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling. Mol. Cell. Biol.
2009, 29, 4235–4249. [CrossRef] [PubMed]
25. Ishay-Ronen, D.; Diepenbruck, M.; Kalathur, R.K.R.; Sugiyama, N.; Tiede, S.; Ivanek, R.; Bantug, G.;
Morini, M.F.; Wang, J.; Hess, C.; et al. Gain Fat—Lose Metastasis: Converting Invasive Breast Cancer Cells
into Adipocytes Inhibits Cancer Metastasis. Cancer Cell 2019, 35, 17–32. [CrossRef] [PubMed]
26. Li, J.; Duns, G.; Westers, H.; Sijmons, R.; Berg, A.V.D.; Kok, K. SETD2: An epigenetic modifier with tumor
suppressor functionality. Oncotarget 2016, 7, 50719–50734. [CrossRef] [PubMed]
27. Viaene, A.N.; Santi, M.; Rosenbaum, J.; Li, M.M.; Surrey, L.F.; Nasrallah, M.L.P. SETD2 mutations in primary
central nervous system tumors. Acta Neuropathol. Commun. 2018, 6, 123. [CrossRef]
28. Moroishi, T.; Hayashi, T.; Pan, W.-W.; Fujita, Y.; Holt, M.V.; Qin, J.; Carson, D.A.; Guan, K.-L. The Hippo
Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell 2016, 167, 1525–1539.e7. [CrossRef]
29. Yang, Y.; Liu, C.; Peng, W.; Lizée, G.; Overwijk, W.W.; Liu, Y.; Woodman, S.E.; Hwu, P. Antitumor T-cell
responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by
anti-OX40. Blood 2012, 120, 4533–4543. [CrossRef]
Cancers 2020, 12, 2310 18 of 20
30. Tu, M.M.; Lee, F.Y.F.; Jones, R.T.; Kimball, A.K.; Saravia, E.; Graziano, R.F.; Coleman, B.; Menard, K.; Yan, J.;
Michaud, E.; et al. Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy. Sci. Adv. 2019, 5,
eaav2437. [CrossRef]
31. Dixon, S.J.; Lemberg, K.M.; Lamprecht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.;
Cantley, A.M.; Yang, W.S.; et al. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell
2012, 149, 1060–1072. [CrossRef] [PubMed]
32. Wu, J.; Minikes, A.; Gao, M.; Bian, H.; Li, Y.; Stockwell, B.R.; Chen, Z.-N.; Jiang, X. Intercellular interaction
dictates cancer cell ferroptosis via Merlin-YAP signalling. Nature 2019, 572, 402–406. [CrossRef] [PubMed]
33. Yang, H.; Liang, S.-Q.; Schmid, R.A.; Peng, R.-W. New Horizons in KRAS-Mutant Lung Cancer: Dawn after
Darkness. Front. Oncol. 2019, 9. [CrossRef] [PubMed]
34. Hausser, J.; Alon, U. Tumour heterogeneity and the evolutionary trade-offs of cancer. Nat. Rev. Cancer 2020,
20, 247–257. [CrossRef]
35. Zhou, S.; Liu, L.; Li, H.; Eilers, G.; Kuang, Y.; Shi, S.; Yan, Z.; Li, X.; Corson, J.M.; Meng, F.; et al. Multipoint
targeting of the PI3K/mTOR pathway in mesothelioma. Br. J. Cancer 2014, 110, 2479–2488. [CrossRef]
36. Bonelli, M.; Digiacomo, G.; Fumarola, C.; Alfieri, R.; Quaini, F.; Falco, A.; Madeddu, D.; La Monica, S.;
Cretella, D.; Ravelli, A.; et al. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces
a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. Neoplasia 2017, 19, 637–648.
[CrossRef]
37. Altomare, D.A.; You, H.; Xiao, G.-H.; Ramos-Nino, M.E.; Skele, K.L.; De Rienzo, A.; Jhanwar, S.C.;
Mossman, B.T.; Kane, A.B.; Testa, J.R. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity,
which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005, 24, 6080–6089.
[CrossRef]
38. Yamaji, M.; Ota, A.; Wahiduzzaman, M.; Karnan, S.; Hyodo, T.; Konishi, H.; Tsuzuki, S.; Hosokawa, Y.;
Haniuda, M. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant
pleural mesothelioma cells. Cancer Med. 2017, 6, 2646–2659. [CrossRef]
39. Sobhani, N.; Corona, S.P.; Zanconati, F.; Generali, D. Cyclin dependent kinase 4 and 6 inhibitors as novel
therapeutic agents for targeted treatment of malignant mesothelioma. Genes Cancer 2017, 8, 495–496.
[CrossRef]
40. Pease, D.F.; Kratzke, R.A. Oncolytic Viral Therapy for Mesothelioma. Front. Oncol. 2017, 7. [CrossRef]
41. Carbone, M.; Yang, H.; Pass, H.I.; Krausz, T.; Testa, J.R.; Gaudino, G. BAP1 and Cancer. Nat. Rev. Cancer
2013, 13, 153–159. [CrossRef] [PubMed]
42. Rathkey, D.; Khanal, M.; Murai, J.; Zhang, J.; Sengupta, M.; Jiang, Q.; Morrow, B.; Evans, C.N.; Chari, R.;
Fetsch, P.; et al. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1
but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA
Methyltransferase Expression. J. Thorac. Oncol. 2020, 15, 843–859. [CrossRef] [PubMed]
43. Guazzelli, A.; Meysami, P.; Bakker, E.; Demonacos, C.; Giordano, A.; Demonacos, C.; Mutti, L. BAP1 Status
Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment. Int. J. Mol. Sci. 2019,
20, 429. [CrossRef]
44. Okonska, A.; Bühler, S.; Rao, V.; Ronner, M.; Blijlevens, M.; Van Der Meulen-Muileman, I.H.; De Menezes, R.X.;
Wipplinger, M.; Oehl, K.; Smit, E.F.; et al. Functional Genomic Screen in Mesothelioma Reveals that Loss of
Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
Mol. Cancer Ther. 2019, 19, 552–563. [CrossRef]
45. Sen, N.; Satija, Y.K.; Das, S. PGC-1α, a Key Modulator of p53, Promotes Cell Survival upon Metabolic Stress.
Mol. Cell 2011, 44, 621–634. [CrossRef]
46. Assaily, W.; Rubinger, D.A.; Wheaton, K.; Lin, Y.; Ma, W.; Xuan, W.; Brown-Endres, L.; Tsuchihara, K.;
Mak, T.W.; Benchimol, S. ROS-Mediated p53 Induction of Lpin1 Regulates Fatty Acid Oxidation in Response
to Nutritional Stress. Mol. Cell 2011, 44, 491–501. [CrossRef]
47. Goldstein, I.; Rotter, V. Regulation of lipid metabolism by p53—Fighting two villains with one sword.
Trends Endocrinol. Metab. 2012, 23, 567–575. [CrossRef]
48. Lacroix, M.; Riscal, R.; Arena, G.; Linares, L.K.; Le Cam, L. Metabolic functions of the tumor suppressor p53:
Implications in normal physiology, metabolic disorders, and cancer. Mol. Metab. 2020, 33, 2–22. [CrossRef]
Cancers 2020, 12, 2310 19 of 20
49. Tian, K.; Bakker, E.; Hussain, M.; Guazzelli, A.; Alhebshi, H.; Meysami, P.; Demonacos, C.; Schwartz, J.-M.;
Mutti, L.; Krstic-Demonacos, M. p53 modeling as a route to mesothelioma patients stratification and novel
therapeutic identification. J. Transl. Med. 2018, 16, 282. [CrossRef]
50. Wang, X.; Simon, R. Identification of potential synthetic lethal genes to p53 using a computational biology
approach. BMC Med. Genom. 2013, 6, 30. [CrossRef]
51. Aning, O.A.; Cheok, C.F. Drugging in the absence of p53. J. Mol. Cell Biol. 2019, 11, 255–264. [CrossRef]
52. Mairinger, F.D.; Walter, R.F.; Ting, S.; Vollbrecht, C.; Kollmeier, J.; Griff, S.; Hager, T.; Mairinger, T.;
Christoph, D.C.; Theegarten, D.; et al. Mdm2 protein expression is strongly associated with survival in
malignant pleural mesothelioma. Future Oncol. 2014, 10, 995–1005. [CrossRef]
53. Di Marzo, D.; Forte, I.M.; Indovina, P.; Di Gennaro, E.; Rizzo, V.; Giorgi, F.; Mattioli, E.; Ianuzzi, C.A.;
Budillon, A.; Giordano, A.; et al. Pharmacological targeting of p53 through RITA is an effective antitumoral
strategy for malignant pleural mesothelioma. Cell Cycle 2013, 13, 652–665. [CrossRef] [PubMed]
54. Walter, R.F.; Werner, R.; Wessolly, M.; Mairinger, E.; Borchert, S.; Schmeller, J.; Kollmeier, J.; Mairinger, T.;
Hager, T.; Bankfalvi, A.; et al. Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for
Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53. J. Oncol. 2018, 2018, 1–10.
[CrossRef] [PubMed]
55. Urso, L.; Cavallari, I.; Silic-Benussi, M.; Biasini, L.; Zago, G.; Calabrese, F.; Conte, P.; Ciminale, V.; Pasello, G.
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
Oncotarget 2017, 8, 44232–44241. [CrossRef] [PubMed]
56. Xu, D.; Liang, S.-Q.; Yang, H.; Bruggmann, R.; Berezowska, S.; Yang, Z.; Marti, T.M.; Hall, S.R.R.; Gao, Y.;
Kocher, G.J.; et al. CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy
in Malignant Pleural Mesothelioma. Mol. Cancer Ther. 2019, 19, 661–672. [CrossRef] [PubMed]
57. Indovina, P.; Marcelli, E.; Di Marzo, D.; Casini, N.; Forte, I.M.; Giorgi, F.; Alfano, L.; Pentimalli, F.; Giordano, A.
Abrogating G2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising
therapeutic approach for mesothelioma. Cancer Biol. Ther. 2014, 15, 380–388. [CrossRef]
58. Destro, A.; Ceresoli, G.; Falleni, M.; Zucali, P.; Morenghi, E.; Bianchi, P.; Pellegrini, C.; Cordani, N.; Vaira, V.;
Alloisio, M.; et al. EGFR overexpression in malignant pleural mesothelioma. Lung Cancer 2006, 51, 207–215.
[CrossRef]
59. Mezzapelle, R.; Miglio, U.; Rena, O.; Paganotti, A.; Allegrini, S.; Antona, J.; Molinari, F.; Frattini, M.;
Monga, G.; Alabiso, O.; et al. Mutation analysis of the EGFR gene and downstream signalling pathway in
histologic samples of malignant pleural mesothelioma. Br. J. Cancer 2013, 108, 1743–1749. [CrossRef]
60. Horvai, A.E.; Li, L.; Xu, Z.; Kramer, M.J.; Jablons, D.; Treseler, P.A. Malignant mesothelioma does not
demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for
c-Erb-B2. Arch. Pathol. Lab. Med. 2003, 127, 465–469.
61. Klampatsa, A.; Achkova, D.Y.; Davies, D.M.; Parente-Pereira, A.C.; Woodman, N.; Rosekilly, J.; Osborne, G.;
Thayaparan, T.; Bille, A.; Sheaf, M.; et al. Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma
using pan-ErbB re-targeted CAR T-cells. Cancer Lett. 2017, 393, 52–59. [CrossRef] [PubMed]
62. Toma, S.; Colucci, L.; Scarabelli, L.; Scaramuccia, A.; Emionite, L.; Betta, P.G.; Mutti, L. Synergistic effect of the
anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines. J. Cell. Physiol.
2002, 193, 37–41. [CrossRef]
63. Popat, S.; Curioni-Fontecedro, A.; Polydoropoulou, V.; Shah, R.; O’Brien, M.; Pope, A.; Fisher, P.; Spicer, J.;
Roy, A.; Gilligan, D.; et al. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single
agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from
the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann. Oncol. 2019, 30, v931.
[CrossRef]
64. Maio, M.; Scherpereel, A.; Calabrò, L.; Aerts, J.; Perez, S.C.; Bearz, A.; Nackaerts, K.; A Fennell, D.;
Kowalski, D.; Tsao, A.S.; et al. Tremelimumab as second-line or third-line treatment in relapsed malignant
mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled
phase 2b trial. Lancet Oncol. 2017, 18, 1261–1273. [CrossRef]
65. Tsao, A.S.; Lin, H.; Carter, B.W.; Lee, J.J.; Rice, D.; Vaporcyan, A.; Swisher, S.; Mehran, R.; Heymach, J.;
Nilsson, M.; et al. Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural
Mesothelioma. J. Thorac. Oncol. 2018, 13, 246–257. [CrossRef]
Cancers 2020, 12, 2310 20 of 20
66. Yu, G.; Wang, L.-G.; Han, Y.; He, Q.-Y. clusterProfiler: An R Package for Comparing Biological Themes
Among Gene Clusters. OMICS A J. Integr. Biol. 2012, 16, 284–287. [CrossRef]
67. Xu, D.; Yang, H.; Berezowska, S.; Gao, Y.; Liang, S.-Q.; Marti, T.M.; Hall, S.R.R.; Dorn, P.; Kocher, G.J.;
Schmid, R.A.; et al. Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural
Mesothelioma. Cancers 2019, 11, 1502. [CrossRef]
68. Yang, H.; Liang, S.-Q.; Xu, D.; Yang, Z.; Marti, T.M.; Gao, Y.; Kocher, G.J.; Zhao, H.; Schmid, R.A.; Peng, R.-W.
HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant
KRAS-mutant lung cancer. Oncogenesis 2019, 8, 45. [CrossRef]
69. Li, J.; Lu, Y.; Akbani, R.; Ju, Z.; Roebuck, P.L.; Liu, W.; Yang, J.-Y.; Broom, B.M.; Verhaak, R.G.W.; Kane, D.W.;
et al. TCPA: A resource for cancer functional proteomics data. Nat. Methods 2013, 10, 1046–1047. [CrossRef]
70. Yang, H.; Zhao, L.; Yao, F.; Gao, Y.; Marti, T.M.; Schmid, R.A.; Peng, R.-W. Integrative Pharmacogenomic
Profiling Identifies Novel Cancer Drugs and Gene Networks Modulating Ferroptosis Sensitivity in Pan-Cancer.
2020. Available online: https://doi.org/10.21203/rs.3.rs-34574/v1 (accessed on 3 July 2020).
71. Alonso-López, D.; Campos-Laborie, F.J.; A Gutiérrez, M.; Lambourne, L.; Calderwood, M.A.; Vidal, M.;
Rivas, J.D. APID database: Redefining protein–protein interaction experimental evidences and binary
interactomes. Database 2019, 2019. [CrossRef] [PubMed]
72. Samstein, R.M.; Lee, C.-H.; Shoushtari, A.N.; Hellmann, M.D.; Shen, R.; Janjigian, Y.Y.; Barron, D.A.; Zehir, A.;
Jordan, E.J.; Omuro, A.; et al. Tumor mutational load predicts survival after immunotherapy across multiple
cancer types. Nat. Genet. 2019, 51, 202–206. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
